https://www.selleckchem.com/pr....oducts/Aurora-A-Inhi
05 in MutSigCV software were analyzed for pathway enrichment. These genes were mainly enriched in four pathways, including MAPK mTOR, p53/cell cycle, and JAK-STAT pathways. Finally, there were 15 genes four pathways that had marketed approved target drugs. To conclude, LRP1B, MYC, NF1, and KEAP1 were the candidate key driver genes for liver cancer, which might provide new insights for targeted therapy of liver cancer.Thrombosis is the most common complication in BCR-ABL1 negative myeloproliferative neoplasms (MPN) that sign
Like
Comment
Share
